La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hunan Jiudian Pharmaceutical Croissance future

Future contrôle des critères 5/6

Hunan Jiudian Pharmaceutical devrait augmenter ses bénéfices et son chiffre d'affaires de 27% et de 17.2% par an respectivement. Le BPA devrait croître de de 26.8% par an. Le rendement des capitaux propres devrait être 23.5% dans 3 ans.

Informations clés

27.0%

Taux de croissance des bénéfices

27.0%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.8%
Taux de croissance des recettes	18.0%
Rendement futur des capitaux propres	23.8%
Couverture par les analystes	Good
Dernière mise à jour	09 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Aug 12

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Jun 23

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

May 21

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Apr 12

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Mar 04

Prévisions de croissance des bénéfices et des revenus

SZSE:300705 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	4,477	881	542	899	6
12/31/2025	3,764	665	369	624	7
12/31/2024	3,189	511	279	600	7
6/30/2024	2,841	455	286	652	N/A
3/31/2024	2,782	417	192	571	N/A
12/31/2023	2,693	368	4	431	N/A
9/30/2023	2,620	371	60	490	N/A
6/30/2023	2,513	338	-86	427	N/A
3/31/2023	2,379	291	-162	369	N/A
1/1/2023	2,326	270	-144	269	N/A
9/30/2022	2,097	243	-55	262	N/A
6/30/2022	1,927	221	-16	163	N/A
3/31/2022	1,799	214	57	176	N/A
1/1/2022	1,628	204	65	191	N/A
9/30/2021	1,451	196	41	149	N/A
6/30/2021	1,317	162	48	166	N/A
3/31/2021	1,096	122	63	148	N/A
12/31/2020	978	82	72	150	N/A
9/30/2020	921	72	83	183	N/A
6/30/2020	891	59	31	144	N/A
3/31/2020	906	52	-15	127	N/A
12/31/2019	924	55	-91	91	N/A
9/30/2019	900	65	-162	64	N/A
6/30/2019	867	73	-176	62	N/A
3/31/2019	811	70	-200	76	N/A
12/31/2018	801	72	-189	68	N/A
9/30/2018	746	67	-160	40	N/A
6/30/2018	680	72	-92	65	N/A
3/31/2018	613	71	N/A	56	N/A
12/31/2017	535	69	N/A	80	N/A
9/30/2017	472	72	N/A	86	N/A
6/30/2017	430	62	N/A	75	N/A
3/31/2017	385	56	N/A	52	N/A
12/31/2016	376	55	N/A	55	N/A
9/30/2016	334	39	N/A	35	N/A
6/30/2016	320	38	N/A	32	N/A
3/31/2016	305	41	N/A	32	N/A
12/31/2015	290	45	N/A	32	N/A
9/30/2015	281	43	N/A	30	N/A
6/30/2015	272	40	N/A	28	N/A
3/31/2015	269	41	N/A	34	N/A
12/31/2014	266	41	N/A	40	N/A
12/31/2013	241	36	N/A	31	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 300705 ( 27% par an) est supérieure au taux d'épargne ( 2.9% ).

Bénéfices vs marché: Les bénéfices de 300705 ( 27% par an) devraient croître plus rapidement que le marché CN ( 21.9% par an).

Croissance élevée des bénéfices: Les bénéfices de 300705 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 300705 ( 17.2% par an) devrait croître plus rapidement que le marché CN ( 13.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 300705 ( 17.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 300705 devrait être élevé dans 3 ans ( 23.5 %)

Hunan Jiudian Pharmaceutical Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.26 in 2Q 2023)

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Investor sentiment deteriorates as stock falls 17%

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Investor sentiment deteriorates as stock falls 31%

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

Dividend increased to CN¥0.32

Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 1Q 2023)

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Investor sentiment improves as stock rises 19%

Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.24 in 3Q 2022)

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.17 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.20 in 2Q 2021)

Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022

Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021

Investor sentiment improved over the past week

Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.097 in 3Q 2020)

Investor sentiment deteriorated over the past week

Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million.

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.11 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.35 (vs CN¥0.23 in FY 2019)

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 17, 2021

Full year 2020 earnings released: EPS CN¥0.34 (vs CN¥0.23 in FY 2019)

New 90-day high: CN¥28.81

New 90-day high: CN¥25.00

Third quarter earnings released

New 90-day high - CN¥20.99

Earnings released

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 22, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance